Cape Town, South Africa | October 5–9, 2025 — At the world’s leading obstetrics and gynecology conference, the FIGO 2025 World Congress, the International Federation of Gynecology and Obstetrics (FIGO) officially announced the inclusion of High-Intensity Focused Ultrasound (HIFU) in its Best Practice Clinical Guideline for the Diagnosis and Treatment of Uterine Fibroids.

This milestone marks the first time a Chinese-developed non-invasive therapy has been recognized by FIGO, the world’s most authoritative organization in women’s health, signifying global academic acknowledgment of China’s contribution to micro- and non-invasive medicine.

A Safer, Organ-Preserving Solution for Women Worldwide

HIFU uses focused ultrasound energy to precisely ablate fibroid tissue from outside the body—without surgery, bleeding, or radiation—preserving the uterus and fertility while minimizing pain and recovery time.
Patients can often resume normal life within a day and begin preparing for pregnancy within three months, offering a compassionate alternative to hysterectomy or myomectomy.

With declining global fertility rates, HIFU provides a meaningful solution that supports women’s reproductive health and the development of the global health and population agenda.

From Chongqing to the World

Developed by Professor Zhibiao Wang and his team at Chongqing Medical University, HAIFU has built a complete ecosystem covering research, engineering, clinical application, and physician training. Its HAIFU® systems—holding fully independent intellectual property rights—have now reached 36 countries and regions, treating over 340,000 patients with organ-preserving, non-invasive procedures.

The technology’s inclusion in FIGO guidelines follows decades of clinical validation and growing international recognition—from ACOG (USA), SOGC (Canada), KSOG (Korea), to NICE (UK)—demonstrating its safety, efficacy, and transformative potential in modern gynecology.

Global Recognition, Shared Future

Led by Prof. Philippe Descamps, then FIGO Vice President and now President of ISMIVS, an international expert group systematically reviewed global clinical evidence. The results confirmed HIFU’s consistent safety, effectiveness, and quality-of-life benefits across thousands of cases worldwide.

“This recognition propels global fibroid management from invasive to non-invasive,” FIGO noted in its report.

HAIFU Technology will continue advancing micro- and non-invasive innovations, helping more women worldwide benefit from “no incision, no pain, and organ-preserving” treatments—bringing Chinese wisdom and compassion to global healthcare.